

In Scotland, a newly licensed medicine is routinely available in a health board only after it has been:

- accepted for use in NHS Scotland by the Scottish Medicines Consortium (SMC), and
- accepted for use by the health board's Area Drug and Therapeutics Committee (ADTC).

All medicines accepted by SMC are available in Scotland, but may not be considered 'routinely available' within a particular health board because of available services and preferences for alternative medicines.

'Routinely available' means that a medicine can be prescribed by the appropriately qualified person within a health board.

Each health board has an ADTC. The ADTC, Grampian Area Drug and Therapeutics Committee, is responsible for advising NHS Grampian health board on all aspects of the use of medicines.

Medicines routinely available within NHS Grampian are usually included in the Grampian Joint Formulary. The formulary is a list of medicines for use in the health board that has been agreed by the ADTC in consultation with local clinical experts. It offers a choice of medicines for healthcare professionals to prescribe for common medical conditions. A formulary can help improve safety as prescribers are likely to become more familiar with the medicines in it and also helps make sure that standards of care are consistent across the health board.

### **How does the health board decide which new medicines to make routinely available for patients?**

The ADTC in a health board will consider national and local guidance before deciding whether to make a new medicine routinely available.

#### **What national guidance does the ADTC consider?**

- SMC advice: The SMC considers newly licensed medicines and advises health boards in Scotland whether they should be available. When SMC considers a new medicine for the NHS in Scotland, it looks at:
  - how well the medicine works,
  - which patients might benefit from it,
  - whether it is as good or better than medicines the NHS already uses to treat the medical condition, and
  - whether it is good value for money.
- In the table below, national guidance usually refers to SMC advice. Links to SMC advice for individual medicines are also included in the table.
- In some cases, other agencies may also provide guidance on how medicines should be used. For example, Healthcare Improvement Scotland issues alerts to advise if National Institute for Health and Care Excellence Multiple Technology Appraisals (NICE MTAs) are applicable in Scotland.

#### **What local guidance does the ADTC consider?**

- Advice from local clinical experts who would be expected to prescribe a particular medicine, where that service is available in a health board.

### Why is a particular medicine not routinely available in NHS Grampian?

- This is usually because the medicine is not recommended for use in NHS Scotland by the SMC.
- The medicine may not be routinely available in a health board, particularly in smaller health boards, because there is not a suitable specialist who may use the medicine.
- There may also be differences as to which medicines are preferred in health boards. Sometimes SMC accepts more than one medicine for treating a specific medical condition. Clinical experts in each health board consider whether to add new medicines to their formulary and advise the ADTC. Sometimes it is agreed that established medicines are a better choice than new medicines.

### What happens if a particular medicine is not routinely available in NHS Grampian?

- If a medicine is not routinely available and not included in the Grampian Joint Formulary and there are no suitable alternatives on the formulary, a healthcare professional can request to prescribe a medicine that is not on the formulary if they think you will benefit from using it. All health boards have procedures in place to consider requests when a healthcare professional feels a medicine that is not on the formulary would be right for a particular patient.

The table below lists NHS Grampian's latest decisions on medicines.

If you need more information on medicines decisions in NHS Grampian, please email [gram.formularyteam@nhs.scot](mailto:gram.formularyteam@nhs.scot).




Image courtesy of Baitong333 - image ID: 100128772/ [FreeDigitalPhotos.net](http://FreeDigitalPhotos.net)

This document is also available in large print and other formats and languages, upon request. Please call NHS Grampian Corporate Communications on (01224) 551116 or (01224) 552245.

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
amivantamab 350mg concentrate for solution for infusion (Rybrevant®)	<a href="#">2878</a>	In combination with carboplatin and pemetrexed for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon20 insertion mutations.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	20/01/2026
buprenorphine 0.4mg, 2mg, 8mg sublingual tablets (Subutex®)		Substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment.	This medicine is now withdrawn from use/discontinued	20/01/2026
ciclosporin 1mg/mL eye drops, solution in multi-dose container (Vevizye®)	<a href="#">2873</a>	Treatment of moderate to severe dry eye disease (keratoconjunctivitis sicca) in adult patients, which has not improved despite treatment with tear substitutes.  <b>SMC restriction:</b> severe keratitis in adult patients with dry eye disease.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	20/01/2026
clascoterone 10mg/g cream (Winlevi®)	<a href="#">2894</a>	Topical treatment of acne vulgaris in patients 12 years of age and older.	Not routinely available as not recommended for use in NHS Scotland, SMC 2894 <a href="https://scottishmedicines.org.uk/media/9656/clascoterone-winlevi-non-sub-final-dec-2025-for-website.pdf">https://scottishmedicines.org.uk/media/9656/clascoterone-winlevi-non-sub-final-dec-2025-for-website.pdf</a>	20/01/2026
daratumumab 1,800mg solution for injection (Darzalex®)	<a href="#">2895</a>	As monotherapy for the treatment of adult patients with smouldering multiple myeloma at high risk of developing multiple myeloma.	Not routinely available as not recommended for use in NHS Scotland, SMC 2895 <a href="https://scottishmedicines.org.uk/media/9657/daratumumab-darzalex-non-sub-final-dec-2025-for-website.pdf">https://scottishmedicines.org.uk/media/9657/daratumumab-darzalex-non-sub-final-dec-2025-for-website.pdf</a>	20/01/2026
delgocitinib 20mg/g cream (Anzupgo®)	<a href="#">2817</a>	Treatment of moderate to severe chronic hand eczema (CHE) in adults for whom topical corticosteroids are inadequate or inappropriate.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	20/01/2026
diclofenac 75mg/mL solution for injection (Akis®)		Acute forms of pain, including renal colic, exacerbations of osteo- and rheumatoid arthritis, acute back pain, acute gout, acute trauma and fractures, and post-operative pain.	This medicine is now withdrawn from use/discontinued	20/01/2026

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
dupilumab 200mg, 300mg solution for injection in pre-filled pen and syringe (Dupixent®)	<a href="#">2896</a>	Treatment of chronic spontaneous urticaria (CSU) in patients aged 12 years and older whose disease is not adequately controlled with H1 antihistamine treatment.	Not routinely available as not recommended for use in NHS Scotland, SMC 2896 <a href="https://scottishmedicines.org.uk/media/9658/dupilumab-dupixent-non-sub-final-dec-2025-for-website.pdf">https://scottishmedicines.org.uk/media/9658/dupilumab-dupixent-non-sub-final-dec-2025-for-website.pdf</a>	20/01/2026
durvalumab 50mg/mL concentrate for solution for infusion (Imfinzi®)	<a href="#">2797</a>	In combination with carboplatin and paclitaxel for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with: <ul style="list-style-type: none"> <li>- durvalumab as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR)</li> <li>- durvalumab in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR)</li> </ul> - Treatment of symptomatic anaemia associated with chronic renal failure in adult and paediatric patients.           - Prevention of anaemia of prematurity in infants with a birth weight of 750 to 1500 g and a gestational age of less than 34 weeks.           - Treatment of symptomatic anaemia in adult patients with non-myeloid malignancies receiving chemotherapy.           - Increasing the yield of autologous blood from patients in a pre-donation programme.	Routinely available in line with national guidance, SMC 2797 <a href="https://scottishmedicines.org.uk/media/9478/durvalumab-imfinzi-final-sept-2025-for-website.pdf">https://scottishmedicines.org.uk/media/9478/durvalumab-imfinzi-final-sept-2025-for-website.pdf</a>	20/01/2026
epoetin beta 20,000 units/0.6mL solution for injection pre-filled syringes (NeoRecormon®)			This medicine is now withdrawn from use/discontinued	20/01/2026
exagamglogene autotemcel 4-13 x 10 <sup>6</sup> cells/mL dispersion for infusion dispersion for infusion (Casgevy®)	<a href="#">2852</a>	For the treatment of sickle cell disease in patients 12 years of age and older with recurrent vaso-occlusive crises who have the βS/βS, βS/β+ or βS/β0 genotype, for whom haematopoietic stem cell transplantation is appropriate and a human leukocyte antigen matched related haematopoietic stem cell donor is not available.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	20/01/2026

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
givinostat 8.86mg/mL oral suspension (Duvyzat®)	<a href="#">2856</a>	Treatment of Duchenne muscular dystrophy (DMD) in patients 6 years of age and older.  <b>SMC restriction:</b> patients who are ambulant when they initiate givinostat treatment; this includes patients who are ambulant when they initiate givinostat and become non-ambulant during treatment.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	20/01/2026
guselkumab 100mg, 200mg solution for injection in pre-filled pen, 200mg concentrate for solution for infusion (Tremfya®)	<a href="#">2850</a>	For the treatment of adults with moderately to severely active Crohn's disease who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic treatment.	Routinely available in line with national guidance, SMC 2850 <a href="https://scottishmedicines.org.uk/media/9544/guselkumab-tremfya-cd-abb-final-oct-2025-for-website.pdf">https://scottishmedicines.org.uk/media/9544/guselkumab-tremfya-cd-abb-final-oct-2025-for-website.pdf</a>	20/01/2026
hydrocortisone butyrate 0.1% ointment (Locoid®)		In adults, children and infants above 3 months of age. The product is recommended for treatment of inflammatory skin disorders not caused by micro-organisms e.g. eczema, dermatitis and psoriasis.	This medicine is now withdrawn from use/discontinued	20/01/2026
insulin aspart 100units/mL solution for injection in pre-filled pen (Fiasp® FlexTouch®)		Treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.	This medicine is now withdrawn from use/discontinued	20/01/2026
insulin degludec 100units/mL solution for injection in pre-filled pen (Tresiba® FlexTouch®)		Treatment of diabetes mellitus in adults, adolescents and children from the age of 1 year.	This medicine is now withdrawn from use/discontinued	20/01/2026
iptacopan 200mg hard capsules (Fabhalta®)	<a href="#">2889</a>	Treatment of adult patients with complement 3 glomerulopathy (C3G) in combination with a renin-angiotensin system (RAS) inhibitor, or in patients who are RAS-inhibitor intolerant, or for whom a RAS inhibitor is contraindicated.	Not routinely available as not recommended for use in NHS Scotland, SMC 2889 <a href="https://scottishmedicines.org.uk/media/9629/iptacopan-fabhalta-non-sub-final-nov-2025-for-website.pdf">https://scottishmedicines.org.uk/media/9629/iptacopan-fabhalta-non-sub-final-nov-2025-for-website.pdf</a>	20/01/2026

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
Kaletra® 100mg/25mg, 200mg/50mg tablets (lopinavir/ritonavir)		In combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children above the age of 2 years.	This medicine is now withdrawn from use/discontinued	20/01/2026
leniolisib 70mg film-coated tablet (Joenja®)	<a href="#">2836</a>	Treatment of activated phosphoinositide 3-kinase delta (PI3K-delta) syndrome (APDS) in adult and paediatric patients 12 years of age and older.	Not routinely available in NHS Grampian. If local need identified contact the Pharmacist Team Leader/Principal Pharmacist - Supply (ARI)	20/01/2026
lopinavir/ritonavir 200mg/50mg tablets		In combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children above the age of 2 years.	This medicine is now withdrawn from use/discontinued	20/01/2026
maralixibat 9.5mg/mL oral solution oral solution (Livmarli®)	<a href="#">2806</a>	Treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 2 months of age and older.  <b>SMC restriction:</b> for use in patients whose condition has not responded to standard of care medicines.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	20/01/2026
marstacimab 150mg solution for injection in pre-filled pen (Hympavzi®)	<a href="#">2759</a>	For routine prophylaxis of bleeding episodes in patients 12 years of age and older, weighing at least 35 kg, with:  - severe haemophilia A (congenital factor VIII deficiency, FVIII < 1%) without factor VIII inhibitors, or - severe haemophilia B (congenital factor IX deficiency, FIX < 1%) without factor IX inhibitors.  <b>SMC restriction:</b> severe haemophilia B (congenital factor IX deficiency, FIX < 1%) without factor IX inhibitors.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	20/01/2026

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
mirikizumab 100mg solution for injection in pre-filled pen, 300mg concentrate for solution for infusion (Omvoh®)	<a href="#">2822</a>	For the treatment of adults with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.	Routinely available in line with national guidance, SMC 2822 <a href="https://scottishmedicines.org.uk/media/9368/mirikizumab-omvoh-abb-final-july-2025-for-website.pdf">https://scottishmedicines.org.uk/media/9368/mirikizumab-omvoh-abb-final-july-2025-for-website.pdf</a>	20/01/2026
nivolumab 10mg/mL concentrate for solution for infusion (Opdivo®)	<a href="#">2820</a>	In combination with ipilimumab for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high colorectal cancer in the following setting: first-line treatment of unresectable or metastatic colorectal cancer.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	20/01/2026
osimertinib 40mg, 80mg film-coated tablets (Tagrisso®)	<a href="#">2736</a>	In combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adults with advanced non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.	Routinely available in line with national guidance, SMC 2736 <a href="https://scottishmedicines.org.uk/media/9260/osimertinib-tagrisso-final-june-2025-for-website.pdf">https://scottishmedicines.org.uk/media/9260/osimertinib-tagrisso-final-june-2025-for-website.pdf</a>	20/01/2026
paclitaxel 6mg/mL concentrate for solution for infusion	<a href="#">125</a>	[Off-label use] paclitaxel (weekly) in combination with trastuzumab plus pertuzumab for the first-line treatment of adults with HER2-positive metastatic or locally recurrent unresectable breast cancer who are considered fit for treatment with pertuzumab plus trastuzumab plus a taxane.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	20/01/2026
pembrolizumab 25mg/mL concentrate for solution for infusion (Keytruda®)	<a href="#">2767</a>	In combination with carboplatin and paclitaxel, for the first-line treatment of primary advanced or recurrent endometrial carcinoma in adults.	Routinely available in line with national guidance, SMC 2767 <a href="https://scottishmedicines.org.uk/media/9261/pembrolizumab-keytruda-final-june-2025-amended-110625-for-website.pdf">https://scottishmedicines.org.uk/media/9261/pembrolizumab-keytruda-final-june-2025-amended-110625-for-website.pdf</a>	20/01/2026

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
pirtobrutinib 50mg, 100mg film-coated tablets (Jaypirca®)	<a href="#">2897</a>	As monotherapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have been previously treated with a Bruton's tyrosine kinase (BTK) inhibitor.	Not routinely available as not recommended for use in NHS Scotland, SMC 2897 <a href="https://scottishmedicines.org.uk/media/9661/pirtobrutinib-jaypirca-non-sub-final-dec-2025-for-website.pdf">https://scottishmedicines.org.uk/media/9661/pirtobrutinib-jaypirca-non-sub-final-dec-2025-for-website.pdf</a>	20/01/2026
progesterone 400mg soft vaginal capsules (Prometrium®)	<a href="#">2869</a>	The prevention of miscarriage in women presenting with bleeding in the first trimester of pregnancy and have a history of recurrent miscarriages.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	20/01/2026
semaglutide, 0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg FlexTouch solution for injection in pre-filled pen (Wegovy®)	<a href="#">2497</a>	<p>As an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of <math>\geq 30\text{kg}/\text{m}^2</math>* (obesity) in the presence of at least one weight-related comorbidity.</p> <p><b>Restrictions:</b></p> <ul style="list-style-type: none"> <li>- as a second-line choice if tirzepatide is not tolerated and,</li> <li>- for patients in the bariatric surgical service until their bariatric surgery and</li> <li>- at a maximum maintenance dose of 2.4mg once per week</li> </ul> <p>*a lower BMI cut-off may be more appropriate for members of minority ethnic groups known to be at equivalent risk of the consequences of obesity at a lower BMI than the white population.</p>	Routinely available in line with local guidance	20/01/2026
serplulimab 10mg/mL concentrate for infusion (Hetronify®)	<a href="#">2840</a>	In combination with carboplatin and etoposide for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).	Not routinely available as not recommended for use in NHS Scotland, SMC 2840 <a href="https://scottishmedicines.org.uk/media/9662/serplulimab-hetronify-final-dec-2025-for-website.pdf">https://scottishmedicines.org.uk/media/9662/serplulimab-hetronify-final-dec-2025-for-website.pdf</a>	20/01/2026

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
sotrovimab 500mg concentrate for solution for infusion (Xevudy®)		For the treatment of symptomatic adults and adolescents (aged 12 years and over and weighing at least 40 kg) with acute covid-19 infection who do not require oxygen supplementation and who are at increased risk of progressing to severe covid infection.	This medicine is now withdrawn from use/discontinued	20/01/2026
Suboxone® 2mg/0.5mg, 8mg/2mg, 16mg/4mg sublingual tablets (buprenorphine/naloxone)		Substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. Suboxone is indicated in adults and adolescents over 15 years of age who have agreed to be treated for addiction.	This medicine is now withdrawn from use/discontinued	20/01/2026
terbutaline 0.5mg/mL solution for injection ampoules (Bricanyl®)		<ul style="list-style-type: none"> <li>- Bronchodilation</li> </ul> <p>Terbutaline is a selective beta2-adrenergic agonist recommended for the relief of bronchospasm in bronchial asthma and other bronchopulmonary disorders in which bronchospasm is a complicating factor.</p> <ul style="list-style-type: none"> <li>- For the short term management of uncomplicated premature labour</li> </ul> <p>To arrest labour between 22 and 37 weeks of gestation in patients with no medical or obstetric contraindication to tocolytic therapy.</p>	This medicine is now withdrawn from use/discontinued	20/01/2026

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
tirzepatide 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg solution for injection in pre-filled pen (Mounjaro®)	<a href="#">2653</a>	<p>As an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of <math>\geq 30\text{kg}/\text{m}^2</math>* (obesity) in the presence of at least one weight-related comorbidity.</p> <p><b>Restriction:</b> for patients in the bariatric surgical service until their bariatric surgery.</p> <p>*a lower BMI cut-off may be more appropriate for members of minority ethnic groups known to be at equivalent risk of the consequences of obesity at a lower BMI than the white population.</p>	Routinely available in line with local guidance	20/01/2026
trastuzumab deruxtecan 100mg powder for concentrate for solution for infusion (Enhertu®)	<a href="#">2888</a>	Treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low or HER2-ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment.	<p>Not routinely available as not recommended for use in NHS Scotland, SMC 2888  <a href="https://scottishmedicines.org.uk/media/9632/trastuzumab-deruxtecan-enhertu-non-sub-final-nov-2025-for-website.pdf">https://scottishmedicines.org.uk/media/9632/trastuzumab-deruxtecan-enhertu-non-sub-final-nov-2025-for-website.pdf</a></p>	20/01/2026
zolbetuximab 100mg powder for concentrate for solution for infusion (Vylory®)	<a href="#">2839</a>	In combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma whose tumours are Claudin (CLDN) 18.2 positive.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	20/01/2026